<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">256</article-id><article-id pub-id-type="doi">10.36691/RJA256</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">MODERN REPRESENTATIONS ABOUT ETIOPATHOGENIC ASPECTS OF DIAGNOSTICS AND TREATMENT OF RSV INFECTION IN NEWBORNS IN KRASNODAR REGION AS AN EXAMPLE</article-title><trans-title-group xml:lang="ru"><trans-title>Современные представления об этиопатогенетических аспектах диагностики и лечения РСВ инфекций у новорожденных детей на примере Крас-нодарского края</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Burlutskaia</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Бурлуцкая</surname><given-names>А В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Firsova</surname><given-names>V N</given-names></name><name xml:lang="ru"><surname>Фирсова</surname><given-names>В Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sharova</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Шарова</surname><given-names>Е В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kuban Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО КубГМУ Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Regional Clinical Hospital for Children</institution></aff><aff><institution xml:lang="ru">ГБУЗ ДККБ МЗ КК, г. Краснодар</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2017</year></pub-date><volume>14</volume><issue>1S</issue><issue-title xml:lang="en">VOL 14, NOS1 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 14, №S1 (2017)</issue-title><fpage>158</fpage><lpage>163</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Фармарус Принт Медиа</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2021-11-01"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/256">https://rusalljournal.ru/raj/article/view/256</self-uri><abstract xml:lang="en"><p/></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Богданова А.В. Хроническая обструктивная болезнь легких у детей. В кн.: Хроническая обструктивная патология легких у взрослых и детей. Руководство для врачей / А.В. Богданова, С.В. Старевская, С.Д. Попов / Под ред. А.Н. Кокосова. СПб.: СпецЛит, 2004: 263-285.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Бойцова Е.В. Облитерирующий бронхиолит у детей. В кн.: Хроническая обструктивная патология легких у взрослых и детей. Руководство для врачей / Е.В. Бойцова / Под ред. А.Н. Кокосова. СПб.: СпецЛит, 2004: 285-302.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Волков И.К. Эмфизема легких у детей / Волков И.К. / Под ред. А.В. Аверьянова // В кн.: Эмфизема легких (серия монографий Российского респираторного общества). - М.: Атмосфера, 2009: 92-97.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Геппе Н.А.Новая рабочая классификация бронхолегочных заболеваний у детей / Н.А. Геппе, Н.Н. Розинова, И.К. Волков [и др.] // Доктор. Ру. 2009; 1: 7-13.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Давыдова И.В. Формирование, течение и исходы бронхолегочной дисплазии у детей: Автореф. дисс.. докт. мед. наук. М., 2010.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Дементьева Г.М. Повторные и хронические бронхолегочные заболевания в раннем возрасте у детей, находившихся на искусственной вентиляции легких в неонатальном периоде / Г.М. Дементьева, Т.Б. Кузьмина, Л.С. Балева [и др.] // Рос. вестн. перинатол. и пед. 1997; 1: 21-25.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Козарезов С.Н. Клинико-патогенетические аспекты бронхолегочной дисплазии в стадии хронической болезни: Автореф. дисс.канд. мед. наук. Минск, 2010.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Козлов И.Г. Иммунотерапия: вчера, сегодня, завтра / И.Г. Козлов, М.А. Тимаков // Педиатрия. 2009; 87 (4): 140-149. 190 Неонатологія, хірургія та перинатальна медицина Т. ІІ, № 4(6), 2012</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Лесфилд С. Бронхолегочная дисплазия / С. Лесфилд // В кн.: Р.Э. Берман, Р.М. Клигман, Х.Б. Джонсон. Педиатрия по Нельсону: Пер. с англ. Т. 4. М.: ООО «Рид Элсивер», 2009: 589-591.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Овсянников Д.Ю. Бронхолегочная дисплазия у детей первых трех лет жизни: Автореф. дисс. докт. мед. наук. М., 2010.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Пятеркина О.Г. Течение и исходы бронхолегочной дисплазии у детей в Республике Татарстан / О.Г. Пятеркина, Д.С. Шагиахметова, Л.В. Храмова [и др.]// XIX Национальный конгресс по болезням органов дыхания. Под ред. А.Г. Чучалина. М.: ДизайнПресс, 2009: 95.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Рудакова А.В. Эффективность затрат на профилактику тяжелой реапираторно-синцитиальной инфекции паливизумабом у недоношенных детей / А.В. Рудакова // Клиническая фармакология и фармакоэкономика.- 2010, 1(3): 13-18.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Самсонова М.И. Результаты бактериологических исследований при хронических неспецифических заболеваниях легких у детей в РС(Я) / М.И. Самсонова, О.Г. Чойдонова, Л.Е. Николаева // XIX Национальный конгресс по болезням органов дыхания. Под ред. А.Г. Чучалина. М.: ДизайнПресс, 2009: 105.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Спичак Т.В. Постинфекционный облитерирующий бронхиолит у детей / Т.В. Спичак // М.: Научный мир, 2005: 80.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Шунько Я.Е. Информационное письмо о нововведениях в системе здравоохранения: Профилактика респираторно-синцитиальной вирусной инфекции у детей групп высокого риска / Е.Е. Шунько, А.Т. Лакша, В.А. Жовнир / №291 - 2011.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Allen J. American Thoracic Society. Statement on the care of the child with chronic lung disease of infancy and childhood / J Allen, R Zwerdling, R Ehrenkranz [ et al.] // Am. J. Respir. Crit. Care Med. 2003; 168: 356-396.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>American Academy of pediatrics. Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm Infants. Pediatrics. 2002; 109 (2): 330-338.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Baraldi E, Filippone M. Chronic lung disease after premature birth. N. Engl. J. Med. 2007; 357: 1946-1955.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Behrman R. E. Textbook of pediatrics. 16 th edition / R. E. Behrman, R. M. Kliegman, W. E. Nelson // London: Elsevier Saunders; 2000.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Boyce TG. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid / TG Boyce, BG Mellen, EF Mitchel [et al.]// J. Pediatr. 2000; 137 (6): 865-870.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Christakis D. A. Variation in inpatient diagnostic testing and management of bronchiolitis / D.A. Christakis, C. A. Cowan, M. M. Garrison [et al] // Pediatrics. 2005; 115:878-884.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Cost-Effectiveness of Palivizumab Against Respiratory Syncytial Viral Infection in High-Risk Children in Austria / Resch В., Gusenleitner W., Nuijten M.J.C. [et al.] / Clin Ther. 2008;30:749-760.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Eber E, Zach M S. Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy) / E Eber, M S. Zach // Thorax. 2001; 56: 317-323.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Fitzgerald D.A. Preventing РСВ bronchiolitis in vulnerable infants: The role of palivizumab / D.A. Fitzgerald // Paediatric Respiratory Reviews.-2009.-10.-Р.143-147.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Hall С.В. Respiratory Syncytial Virus And Parainfluenza Virus / С.В. Hall // N Engl J Med, 2001, 344(25): 1917-1928.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hyvarinen MK. Lung function and bronchial hyperresponsiveness 11 years after hospitalization for bronchiolitis / MK. Hyvarinen // Acta Paed. 2007; 96: 1464-1469.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Jeng SF Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomesin very-low-birth infants / SF Jeng, CH Hsu, PN Tsao [et al] // Dev. Med. Child Neurol. 2008; 50 (1): 51-57.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Jones MH Postinfections bronhiolitis obliterans / MH Jones, PM Pitresz, RT Stein // Pediatric Pulmonology.-2004; 26: 64-65.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nuijten М. Cost effectiveness of palivizumab in children with congenital heart disease in Germany / М. Nuijten, M. Lebmeier, W. Wittenberg // Journal of Medical Economics.- 2009; 12(4): 301-308</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Rennie JM A Manual of Neonatal Intensive Care. Oxford University Press/ Rennie JM, Roberton// NRS.-2002: 204-214.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Robinson R. Addressing the burden of respiratory syncytial virus / Am J Health-Syst Pharm.-2008.-V.65(1), S8, S1-S24.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Schroeder A.R. Pulse oximetry in bronchiolitis patients / A. R. Schroeder, A. Marmor, T. B. Newman // Pediatrics. - 2003; 112 (6 Pt 1): 1463.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children. NHS Quality Improvement Scotland [Internet] Available from www.sign.ac.uk [cited January 16, 2009].</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Simon A. Respiratory syncytial virus infection in 406 hospitalised premature infants: results from a prospective / A Simon, RA Ammann, A Wilkesmann [et al.] // German multicentre database. Eur. J. Pediatr. 2007; 166: 1273-1283.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Smyth R. L. Bronchiolitis / R. L. Smyth, P. J. Openshaw // Lancet. - 2006; 368: 312-322.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Wainwright C. A multicenter, randomized, doubleblind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis / C. Wainwright, L. Altamirano, M. Cheney [et al.] // N Engl J Med. 2003; 349: 27-35</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>AAP Policy Statement_Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections / Pediatrics.-2009.-V.124(6): р.1-8. 191</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Acute Respiratory Infections (Update September 2009).</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Bronchiolitis in children. A national clinical guideline, SIGN, 2006.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Chang R.-K.R. Impact of Palivizumab on РСВ Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease / R.-K.R. Chang / Pediatr Cardiol, 2010, 31:90-95.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Guidelines for the use of palivizumab in infants and young children with congenital heart disease (Japan) / Pediatrics International.-2006.-48:190-193</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Heikkinen Т. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis / Т. Heikkinen // Arch Dis Child Fetal Neonatal Ed 2005 90: F64-F68</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Lo'pez C.M. Community-acquired Respiratory Infections in Young Children With Congenital Heart Diseases in the Palivizumab Era / C.M. Lo'pez / Pediatr Infect Dis J,2010; 29:1077-82</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Mitchell J. CARESS: The Canadian Registry of Palivizumab / J. Mitchell / Pediatr Infect Dis J 2011; 30</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Mortality and morbidity among infants at high risk receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis / Checchia PA [et al.] // Pediatr Crit Care Med. 2010 Dec 31. [Epub ahead of print]</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Nuijten M. Cost effectiveness of palivizumab in children with congenital heart disease in Cost-Effectiveness of Palivizumab Against Respiratory Syncytial Viral Infection in High-Risk Children in Austria Bernhard Resch / M. Nuijten // Journal of Medical Economics, 2009; 12(4): 301-308.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Nuijten M.J.C. Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children. A UK Analysis / M.J.C. Nuijten / Pharmacoeconomics 2007; 25 (1): 55-71.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry / Frogel М. [et al.] // Journal of Perinatology. -2008,1-7</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Prevention of respiratory syncytial virus infection. Canadian Paediatric Society / Paediatr Child Health 2009; 14(8):521-6</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Prevention und Therapie der bronchopulmonalen Dysplasie Frühgeborener, 2010</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Recommendations for the use of palivizumab in the prevention of РСВ infection in late preterm infants (32(1) to 35(0) weeks of gestation. / Anales de pediatria.- 2010.-v.73(2): p. 98.e1-4.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Resch B. Cost-Effectiveness of Palivizumab Against Respiratory Syncytial Viral Infection in High-Risk Children in Austria / B. Resch / Clin Ther. 2008; 30:749760.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Simoes E.A.F. Immunoprophylaxis of respiratory syncytial virus: global experience / E.A.F. Simoes / Respir Res, 2002, 3(s1):S26-S33.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Van de Steen O. Respiratory Syncytial Virus as Cause of Lower Respiratory Tract Infection in Young Children in Central and Eastern Europe / O.Van de Steen, M. Gunjaca, V. Klepac [at al. ]/ Poster presented at the 4th Congress of the European Academy of Paediatric Societies ( October 5-9, 2012, Istanbul).</mixed-citation></ref></ref-list></back></article>
